GASTFOX

Gastfox is a clinical-stage biotechnology company headquartered in Tokyo, Japan, dedicated to developing innovative therapies for gastrointestinal (GI) motility disorders. Spun out from the University of Tokyo, the company leverages the research of Professor Masaaki Tokunaga to address significant unmet needs in conditions such as gastroparesis and functional dyspepsia. Its lead candidate, GFX-101, is a selective small molecule ghrelin receptor agonist designed to enhance gastric motility and alleviate debilitating symptoms. Gastfox aims to provide a superior alternative to existing prokinetic agents, which often have limited efficacy or safety concerns. The company is backed by prominent investors, including University of Tokyo Edge Capital Partners (UTEC).